30 results about "Disorders pain" patented technology

Provided are compositions and methods of using compositions including probiotics for treatment and prevention of a variety of pain disorders, neurological disorders, and / or physiological disorders. The compositions include one or more bacterium capable of producing γ-Aminobutyric acid (GABA). The bacterium is selected from Bifidobacterium adolescentis, Limosilactobacillus reuteri, and Lactiplantibacillus plantarum.

A pharmaceutical composition comprising a metal channel activator and a glutamic acid modulator is provided. Also provided is a method of treating depressive disorder comprising administering the pharmaceutical composition. Also provided is a method of treating a neurological or neurodegenerative disorder comprising administering the pharmaceutical composition. Also provided is a method of treating a pain disorder comprising administering the pharmaceutical composition.

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Provided are methods to treat, ameliorate, prevent, reverse, decrease the severity and / or duration of a pain-associated disease or condition comprising parenteral administration of a pharmaceutically acceptable formulation comprising a synthetic or recombinantly modified AP0A1BP (AIBP) polypeptide.

Provided are methods to treat, ameliorate, prevent, reverse, decrease the severity and / or duration of a pain-associated disease or condition comprising parenteral administration of a pharmaceutically acceptable formulation comprising a synthetic or recombinantly modified AP0A1BP (AIBP) polypeptide.

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

The invention relates to alkyl dihydroquinoline sulfonamide compounds. The present invention provides compounds of Formula I, # imgabs0 # and pharmaceutically acceptable salts thereof, which are inhibitors of voltage gated sodium channels, in particular Nav1.7. The compounds are useful in the treatment of diseases associated with the activity of sodium channels, such as pain disorders, cough and itching. Also provided are pharmaceutical compositions containing the compounds of the invention.

This invention provides a polypeptide and its applications. The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1 or SE ID NO: 2; the 12th amino acid in the amino acid sequence of the polypeptide is alanine or glutamic acid; the 19th amino acid in the amino acid sequence of the polypeptide is methionine or leucine; the 28th amino acid in the amino acid sequence of the polypeptide is lysine or isoleucine; and the 29th amino acid in the amino acid sequence of the polypeptide is selected from isoleucine, leucine, and tryptophan. The polypeptide provided by this invention has good analgesic function and can selectively inhibit the activation of Nav1.7 channels, thereby inhibiting pain, which has extremely important clinical significance for pain disorders.

The present disclosure provides zinc finger fusion proteins that inhibit expression of Nav1.7 in the nervous system, and methods of using the proteins to treat pain disorders.

The present disclosure relates to compounds of Formula I that exhibit 5-HT2A receptor agonist activity and low 5HT2B receptor agonist activity or deemed 5HT2B receptor agonist inactivity. In at least some cases, such compounds show selectivity for the 5-HT2A receptor over the 5-HT2C receptor. As contemplated herein, phenethylamines may be used for the treatment of neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders including depression, drug (e.g. tobacco, opiate, and cocaine) addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

The present invention provides a cyclobutyldihydroquinolinesulfonamide compound of formula (I) for inhibiting voltage-gated sodium channels, particularly Nav1.7, its enantiomers, diastereomers, atropisomers, mixtures thereof, or pharmaceutically acceptable salts thereof. These compounds can be used to treat diseases associated with sodium channel activity, such as pain disorders, cough and pruritus. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided are atropselective preparations of the compounds of formula (I) and intermediates of the compounds.

Provided are methods to treat, ameliorate, prevent, reverse, decrease the severity and / or duration of a pain-associated disease or condition comprising administration of a pharmaceutically acceptable formulation comprising a glycolysis inhibitor.

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and / or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

Provided herein are prodrugs of phenylalanamines (e.g., magical phenylethylamines) incorporating a vitamin B6-based prodrug moiety (e.g., pyridoxal). Also provided are methods of making such compounds, pharmaceutical compositions thereof, and methods of use thereof, such as for the treatment of psychological health disorders, neurodegenerative disorders, pain disorders, and inflammation, including as part of adjuvant therapy as magical agents. (I) (I)

Among the various aspects of the present disclosure is the provision of targeted protein degradation compositions and methods of use thereof. Disclosed herein is a targeted protein degradation composition comprising a ligand to target a protein of interest conjugated to the machinery of the ubiquitin-proteasome system (UPS) to eliminate the protein of interest. A method to treat a pain disorder that includes administering a targeted protein degradation composition to a subject in need is also disclosed.

The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite.The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.

This disclosure relates to heterocyclic compounds of Formula (I). As contemplated herein, heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

A chemical entity of Formula (I):wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.

This disclosure relates to heterocyclic compounds of Formula (I), Formula (II), and Formula (III) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I), Formula (II), and Formula (III) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. Formula (I), Formula (II), Formula (III).

Provided in the present disclosure is a polypeptide and use thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1 or SE ID NO: 2; a 12th amino acid in the amino acid sequence of the polypeptide is alanine or glutamic acid, a 19th amino acid in the amino acid sequence of the polypeptide is methionine or leucine, a 28th amino acid in the amino acid sequence of the polypeptide is lysine or isoleucine, and a 29th amino acid in the amino acid sequence of the polypeptide is selected from any one of isoleucine, leucine and tryptophan. The polypeptide provided in the present disclosure provides good analgesic function and may selectively inhibit an activation of Nav1.7 channels, thereby inhibiting pain, which is of great clinical importance in pain disorders.

The present invention discloses nitrogen-containing heterocyclic derivatives of somatostatin receptor subtype 4 (SSTR4) small molecule agonists, as well as pharmaceutical compositions, preparation methods, and uses thereof. The nitrogen-containing heterocyclic derivatives of SSTR4 small molecule agonists are represented by formula (I), where specific substituents and definitions are as described herein. The nitrogen-containing heterocyclic derivatives of SSTR4 small molecule agonists exhibit good binding and agonist activity with SSTR4. Such compounds or pharmaceutical compositions thereof have great potential in the treatment and / or prevention of pain disorders associated with the SSTR4 receptor.

Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, nutritional supplements) comprising d9-caffeine. The provided compositions may be useful for treating and / or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, decreasing daytime sleepiness, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to sulfur- and selenium-containing compounds that act as agonists and / or antagonists of cannabinoid receptors, methods of making same, pharmaceutical compositions comprising the same, and methods of treating metabolic disorders, psychiatric disorders, neurological disorders, pain disorders, gastrointestinal disorders, cancers, inflammation-related disorders, substance abuse associated pathologies, and other conditions using the same.

This invention discloses an antibody targeting CGRP and its applications. The antibody or its antigen-binding portion comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2, and CDR-L3. This antibody can specifically bind to human and rat CGRP peptides and α / β subtype CGRP peptides with high affinity, blocking the binding of CGRP to its receptor CGRPR, reducing pain perception, and achieving the treatment of pain disorders such as migraines caused by CGRP. Furthermore, it can also relieve or treat hot flashes.

The invention is based on the discovery of a novel compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Thus, the invention relates to novel lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Provided are compositions and methods of using compositions including probiotics for treatment and prevention of a variety of pain disorders, neurological disorders, and / or physiological disorders. The compositions include one or more bacterium capable of producing γ-Aminobutyric acid (GABA). The bacterium is selected from Bifidobacterium adolescentis, Limosilactobacillus reuteri, and Lactiplantibacillus plantarum.

A chemical entity of Formula (I):wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.

The disclosure relates in some aspects to solid forms of 4-bromo-2,5-dimethoxyphenethylamine (2C-B), such as crystalline polymorphs. In some aspects, the disclosure relates to crystalline Polymorph 1 of 2C-B hydrobromide (HBr). In other aspects, the disclosure provides methods of making the solid forms, compositions comprising the solid forms, and methods of using such solid forms, including their administration to subjects, for example to modulate neurotransmission, increase neuroplasticity or neurogenesis, or treat a medical condition, such as a mental, behavioral, or neurodevelopmental disorder, a neurodegenerative disorder, or a pain disorder.